Leartsakulpanitch Jittrakul, Nganthavee Wimol, Salole Eugene
Outcomes Research, Pfizer Thailand, Bangkok.
J Med Assoc Thai. 2007 Sep;90(9):1925-9.
To estimate the direct out-of-pocket medical costs of treating major diseases attributable to smoking in Thailand in 2006.
A prevalence-based, disease-specific, approach was used to estimate the direct medical costs of treating lung cancer, chronic obstructive pulmonary disease (COPD), and coronary heart disease (CHD) attributable to smoking. Epidemiological parameters were obtained from the literature; historical out-of-pocket cost data were used to estimate 2006 expenditure.
The number of cases attributable to smoking in 2006 was 5,299 for lung cancer, 624,309 for COPD, and 52,605 for CHD. The out-of-pocket expenditures for treatment were 368.49 million baht for lung cancer, 7,714.88 million baht for COPD, and 1,773.65 million baht for CHD. Total smoking-attributable out-of-pocket medical costs amounted to 9,857.02 million baht, 0.48% of GDP in 2006.
The prevalence-based, disease-specific, analysis described here shows that the health and economic impact of smoking in Thailand are substantial, and should be reduced by implementing smoking-cessation and related tobacco control policies of the types found effective in reducing the prevalence of smoking in other countries.
估算2006年泰国因吸烟导致的重大疾病的直接自付医疗费用。
采用基于患病率、特定疾病的方法来估算因吸烟导致的肺癌、慢性阻塞性肺疾病(COPD)和冠心病(CHD)的直接医疗费用。流行病学参数来自文献;利用历史自付费用数据估算2006年的支出。
2006年因吸烟导致的病例数为肺癌5299例、慢性阻塞性肺疾病624309例、冠心病52605例。肺癌的自付治疗费用为3.6849亿泰铢,慢性阻塞性肺疾病为77.1488亿泰铢,冠心病为17.7365亿泰铢。因吸烟导致的自付医疗费用总计98.5702亿泰铢,占2006年国内生产总值的0.48%。
本文所述的基于患病率、特定疾病的分析表明,吸烟对泰国的健康和经济影响巨大,应通过实施在其他国家已证明有效的戒烟及相关烟草控制政策来降低这种影响。